Skip to main content

Table 3 Relationships between LAG-3 and clinical data

From: Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes

Characteristic LAG-3 expression on TILs
 ≤ 14 > 14 p value
Age, n (%)
 < 60 27 (14.8) 128 (70.3) 0.137
 ≥ 60 8 (4.5) 19 (10.4)  
Gender, n (%)
 Female 15 (8.2) 35 (19.2) 0.023
 Male 20 (11) 112 (61.6)  
Smoking status, n (%)
 Non-smoker 27 (14.8) 124 (68.1) 0.308
 Smoker 8 (4.4) 23 (12.7)  
Disease stage, n (%)
 Stage I–II 7 (3.8) 37 (20.3) 0.521
 Stage III–IV 28 (15.5) 110 (60.4)  
Pathological type, n (%)
 I–II 8 (4.4) 47 (25.8) 0.291
 III 27 (14.9) 100 (54.9)  
EBV status, n (%)
 Negative 23 (7.1) 44 (29.7)  < 0.001
 Positive 12 (12.1) 103 (51.1)  
Family history, n (%)
 Yes 8 (4.4) 18 (9.9) 0.107
 No 27 (14.8) 129 (70.9)  
Treatment, n (%)
 Induction chemotherapy 5 (2.7) 35(19.2) 0.213
 Radiotherapy 3 (1.6) 8 (4.5)  
 Radiochemotherapy 26 (14.3) 104 (57.2)  
 Chemotherapy 1(0.5) 0 (0)  
  1. All the p values marked in bold are less than 0.05, which is statistically significant
  2. LAG-3: lymphocyte activating 3; TIL: tumor-infiltrating lymphocyte; EBV: Epstein-Barr virus